Company / Cash & Equivalents
Zimmer Biomet Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$591.9M
FY2025
5-year range
$375.7M / $591.9M
FY2021-FY2025
Trend
+12.6%
vs FY2024
Sector context
#41 of 148
Health Care
What the data says
At $592M, Zimmer Biomet's cash & equivalents ranks #41 of 148 in the Health Care sector. Cash & Equivalents has increased for 3 consecutive years, from $376M in FY2022 to $592M in FY2025.
Based on SEC 10-K filings.
$592M in FY2025 with a 5-year CAGR of -5.9%.
Improved from $416M to $592M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +16.4%
- 5-Year CAGR
- -5.9%
- 10-Year CAGR
- -
Sector benchmark
#41 of 148 in Health CareTop 28% of 148This company $591.9M Sector average $1.2B
▼
-49.7% below sector average
Key checks
Key Insights
- Zimmer Biomet's cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of -5.9%, indicating a declining trend.
- In FY2025, cash & equivalents increased 12.6% year-over-year.
- Ranks #41 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $591.9M | +12.6% |
| FY2024 | $525.5M | +26.4% |
| FY2023 | $415.8M | +10.7% |
| FY2022 | $375.7M | -0.6% |
| FY2021 | $378.1M | -52.9% |
| FY2020 | $802.1M | +29.8% |
| FY2019 | $617.9M | +13.8% |
| FY2018 | $542.8M | +3.5% |
| FY2017 | $524.4M | -51.6% |
| FY2016 | $1.1B | -25.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026